---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-003130"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2022-03-08T23:59:59+00:00"
generated_at: "2026-06-27T00:37:52.683476+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# RxSight Q4 revenue $8.4M (+71% YoY); FY22 guidance $40-44M

## Summary
- Q4 2021 revenue $8.4M, up 71% YoY; FY2021 revenue $22.6M, up 54% YoY.
- Q4 net loss $(15.7)M ($(0.58)/diluted share); adjusted net loss $(12.8)M ($(0.47)/share).
- Sold 45 LDDs in Q4, installed base 206; 2,959 LALs sold in Q4.
- Cash and investments $159.3M; long-term debt $39.8M as of Dec 31, 2021.
- FY2022 revenue expected $40-44M; gross margin 35-36%; OpEx $86-90M.

## SEC filing metadata
- accession: 0000950170-22-003130
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2022-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000095017022003130/0000950170-22-003130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000095017022003130/rxst-20220308.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-003130
- JSON: https://secwatch.observer/filing/0000950170-22-003130.json
- Plain text: https://secwatch.observer/filing/0000950170-22-003130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.